Call closing soon
|
Progress in funded studies
We are happy to announce the following important milestones have been reached in the trials below:
| IMCOVAS First patient included |
On the 26th May 2021 the first participant has been enrolled in the IMCOVAS study, assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes. The study is led by Dr Katie Steenacker and her team in the centre for vaccination evaluation of U Antwerpen with the participation of ULB Erasme, ITM and UZ Gent. Read more>> |
|
| Foot Drop First patient included |
On the 12th May 2021 the first patient has been randomised in the FOOT DROP pilot study: Follow-up and Outcome of Operative Treatment with Decompressive Release Of The Peroneal nerve. The study is led by Prof. Dr. Tom Theys and his team in UZ Leuven with the participation of CHU de Liège, ZOL, AZ Groeninge, ULB Erasme and LUMC (NL) Read more>> |
|
| ARON First patient included |
The first patient was included in the ARON trial, Impact of clinical guidance & point-of-care CRP in children on the 24th February. The study is coming to the end of the run-in phase now and ramping up the number of participating GPs. The study is led by Prof Jan Verbakel and his team at ACHG, KU Leuven with participation from the academic centres of general practice of U Gent, U Antwerp, U Liege, UCL Louvain and VUB. Read more>> |
|
| GonoScreen Recruitment Completed |
In busy COVID-times, the team from the Institute for Tropical Medicine (ITM), headed by Chris Kenyon managed to complete the recruitment of 1014 participants in the GONOSCREEN study in 8 months’ time. Recruiting sites from ITM, UZ Gent, CHU St Pierre, Hôpital Erasme and CHU Liège all contributed to this recruitment success. Participants will be followed up for 1 year and results can be expected by the end of 2022. Read more>> |
|
| Domino Results available |
DOMINO study recruited newly managed IBS (irritable bowel syndrome) patients in primary care and compared treatment with a musculotropic spasmolytic agent, otilonium bromide (OB), to a patient-administered dietary intervention. The study enrolled 483 patients The Chief Investigator of the study is Dr. Jan Tack. Results were presented during a symposium on the 1st April 2021 (link will be available soon) and during the Digestive-Disease week in May 2021. Read more>> |
|
| COV-AID Dawn-Plasma Results available soon |
COV-AID, a study to test the safety and efficacy of anti-inflammatory medications anakinra, tocilizumab and siltuximab in COVID-19 patients with oxygen deficiency and cytokine storm. The study recruited 342 patients between April and December 2020 in 16 participating hospital. It is led by Prof. Dr. Bart Lambrecht and his team in UZ Gent. Read more>> DAWN-PLASMA, A randomized, open-label, adaptive, proof-of-concept clinical trial of Donated Antibodies Working agaiNst COVID-19. The study recruited 489 patients between May 2020 and January 2021 in 21 participating hospitals. It is led by Prof. Dr. Geert Meyfroidt and his team in UZ Leuven Read more>> |
The KCE Trials complete portfolio comprises 35 studies. more info>>
Impact
The last scientific publications are presented here.
Check our dynamic dashboard for real-time recruitment data for all KCE Trials funded studies
